Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Iladatuzumab (MCDS0593A), a humanized IgG1 monoclonal antibody targeting CD79B, serves as a precursor for the synthesis of antibody-drug conjugates (ADCs), such as Iladatuzumab vedotin (DCDS0780A), with potential applications in B-cell non-Hodgkin lymphoma (B-NHL) research [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Iladatuzumab (MCDS0593A), a humanized IgG1 monoclonal antibody targeting CD79B, serves as a precursor for the synthesis of antibody-drug conjugates (ADCs), such as Iladatuzumab vedotin (DCDS0780A), with potential applications in B-cell non-Hodgkin lymphoma (B-NHL) research [1] [2]. |
Synonyms | MCDS0593A |
Molecular Weight | N/A |
CAS No. | 1906205-76-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Iladatuzumab 1906205-76-2 MCDS0593A inhibitor inhibit